期刊
THROMBOSIS AND HAEMOSTASIS
卷 121, 期 7, 页码 976-978出版社
GEORG THIEME VERLAG KG
DOI: 10.1055/a-1326-7028
关键词
thrombosis; acute myocardial infarction; cardiology
The article describes a case of thrombotic coronary side effect in a 72-year-old woman with advanced breast cancer following treatment with abemaciclib, highlighting the need to be cautious of potential cardiotoxic effects of new cancer treatment drugs.
The current article describes a 72-year-old woman who suffered an acute myocardial infarction due to plaque erosion (PE) 2 weeks after abemaciclib treatment onset due to advanced breast cancer. Abemaciclib is a cyclin-dependent kinase 4 and 6 inhibitor that has recently demonstrated efficacy and safety in advanced breast cancer. Of major concern, however, reported thromboembolic rates in randomized clinical trials testing this drug range from 0.6 to 5%. To the best of our knowledge this is the first thrombotic coronary side effect ever reported. We suggest that a treatment that increases thromboembolic risk, such abemaciclib, may have triggered PE in our patient, 15 days after abemaciclib initiation. New molecules are promising in cancer treatment; however, care must be paid to their potential cardiotoxic effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据